The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.

As investment and interest grows in synthetic lethality cancer treatments, Netherlands-headquartered Tesselate Bio hopes to expand horizons within the field by hitting the novel FANCM target and developing its own companion diagnostic.

Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.

Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.